Business Wire

SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.

13.9.2024 09:00:00 EEST | Business Wire | Press release

Share

SamanTree Medical, a leader in innovative surgical imaging solutions, today announced that it has received FDA 510(k) clearance of its Histolog® Scanner for imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture. This groundbreaking Swiss made device is designed to provide real-time, highresolution imaging of fresh tissue surfaces, offering surgeons and pathologists this information for excised tissue.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912995435/en/

The Histolog Scanner in use for rapid visualization of fresh tissue microstructures. (Photo: SamanTree Medical)

The Histolog® Scanner enables real-time, ultra-fast confocal microscopy, allowing for the immediate imaging of resected tissues. This advancement aims to enable physicians to improve their efficiency.

“We are thrilled to introduce the Histolog® Scanner to the U.S. market,” said Dr. Charles Carignan, Executive Chairman of SamanTree Medical. “This FDA clearance is a significant milestone for the company. The ability of the Histolog® Scanner to produce real-time imaging of the internal microstructure of tissues provides surgeons and pathologists with immediate, actionable information.”

Prof. Dr. Alex Mottrie, Head of the Urological Department OLV Hospital, Aalst, Belgium and CEO of ORSI Academy, Ghent, Belgium, commented on the impact of this new technology: “The Histolog® Scanner represents cutting-edge technology in imaging of freshly excised tissue. Its ability to provide high-resolution, real-time images allows us to make more informed decisions.”

Prof. Dr. Ari D. Brooks, Director of Endocrine and Oncologic Surgery, Pennsylvania Hospital, Philadelphia, PA said “The Histolog technology has the potential to significantly reduce the cost, resources and delays associated with the current lack of real-time high-resolution imaging”. Prof Dr. Douglas Scherr, Clinical Director of Urologic Oncology at the Weill Medical College of Cornell University said “Providing imaging data at this resolution has the potential to aid in patient care. In our practice and across Urology, as a field, we are facing limitations in the ability to provide timely decisions to our patients. We will count on the Histolog Scanner to provide us with the ability to image the tissues’ microstructures in real-time and to enable us to make immediate decisions.”

The FDA clearance of the Histolog® Scanner marks a crucial moment in SamanTree Medical’s mission to expand its innovative imaging solutions globally. With this clearance, SamanTree is set to accelerate its U.S. market entry, ensuring that more healthcare providers can leverage the benefits of this cutting-edge technology.

About SamanTree Medical

SamanTree Medical is committed to enhancing clinical outcomes through the development of advanced imaging technologies. The Histolog® Scanner, now FDA-cleared, offers realtime, high-resolution imaging of excised tissue surfaces, providing physicians with this information for immediate assessments. Following the initial commercialization in Europe, the Histolog® Scanner is poised to make a significant impact in the U.S. healthcare market.

For more information, visit www.samantree.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912995435/en/

Contacts

Contact Information
Olivier Delporte
CEO, SamanTree Medical
info@samantree.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Thales at Eurosatory 2026: Ready today. Ready tomorrow15.6.2026 15:01:00 EEST | Press release

As Eurosatory 2026 opens its doors, Thales is pleased to share with you a complete overview of the announcements that will be made during the first day of this international defense and security show. This document centralises all our news, innovations and partnerships, released on June, 15th, 2026 with direct links to the associated press releases: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615204020/en/ Thales at Eurosatory 2026: Ready today. Ready tomorrow. Thales unveils new AI-powered training data analytics platform to enhance military training.Thales launches next-generation 70mm laser-guided rocket dedicated for counter-drone operations.Thales unveils next-generation Bushmaster Mulga Utility Variant.Thales launches RapidStriker, a complete system for protection against drones.Renault Group and Thales unveil 4 TROOP, an innovative tactical vehicle for future land forces engagements. Thales press releases will b

Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery15.6.2026 15:00:00 EEST | Press release

Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide. Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease mo

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 13:00:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission

KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 13:00:00 EEST | Press release

KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige

HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 12:15:00 EEST | Press release

HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612936893/en/ HUI (HUI:VSE) merges traditional and crypto finance: commences continuous trading in Vienna with leading market maker and announces impending token listing on major global exchange Emmanuelle Deba

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye